Medicinal Plants Classification Biosynthesis and ... - Index of

130
Aracely E. Chávez-Piña and Andrés Navarrete
intake, oral nitrate reduction and enterosalivary nitrate circulation. Comparative
Biochemistry and Physiology A, 1997, 118, 939-948.
[40] Lundberg JO; Weitzberg, E; Lundberg JM, Alving, K. Intragastric nitric oxide
production in humans: measurements in expelled air. Gut, 1994, 35, 1543-1546.
[41] MacNaughton, WK; Cirino, G; Wallace JL. Endothelium-derived relaxing factor (nitric
oxide) has protective actions in the stomach. Life Science, 1989, 45, 1869-1876.
[42] Wallace, JL; Cirino, G. The development of gastrointestinal-sparing non-steroidal antiinflammatory
drugs. Trends in Pharmacological Sciences, 1994, 15, 405-406.
[43] Hawkey, CJ; Jones, JI; Atherson, CT; Skelly, MM; Bebb, JR; Fagerholm, U; Jonzon,
B; Karlsson, P; Bjarnason, IT. Gastrointestinal safety of AZD3582, a cyclooxygenase
inhibiting nitric oxide donator: proof of concept study in humans. Gut, 2003, 52,
1537-1542.
[44] Konturek, PC; Brzozowski, T; Kani, J; Konturek, SJ; Hahn, Eg. Nitric oxide-releasing
aspirin protects gastric mucosa against ethanol damage in rats with functional ablation
of sensory nerves. Inflammation research, 2003, 52, 359-365.
[45] Wallace, JL; Muscará, MN; de Nucci, G; Zamuner, S; Cirino, G; del Soldato, P;
Ongini, E. Gastric tolerability and prolonged prostaglandin inhibition in the brain with
a nitric oxide-releasing flurbiprofen derivative, NCX-2216 [3-[4-(2-fluoro-α-methyl-
[1,1´-biphenyl]-4-acetyloxy)-3-methozyphenyl]-2-propenoic acid 4-nitrooxy butyl
ester]. The Journal of Pharmacology and Experimental Therapeutics, 2004, 309,
626-633.
[46] Wallace, JL; McKnight, W; Wilson, TL; del Soldato, P; Cirino, G. Reduction of shockinduced
gastric damage by a nitric oxide-releasing aspirin derivative: role of
neutrophils. American Journal of Physiology and Gastrointestinal Liver Physiology,
1997, 273, 1246-1251.
[47] Fierro, IM; Serhan, CN. Mechanism in anti-inflammation and resolution: the role of
lipoxins and aspirin-triggered lipoxins. Brazilian Journal of Medical and Biological
Research, 2001, 34(5), 555-566.
[48] Claria, J; Serhan, CN. Aspirin triggers previously undescribed bioactive eicosanoids by
human endothelial cell-leukocyte interactions. Proceedings of the National Academy of
Sciences, 1995, 92, 9475-9479.
[49] Shimokawa, T; Smith, WL. Prostaglandin endoperoxide synthase. The aspirin
acetylation region. Journal of Biological Chemistry, 1992, 267, 12387-12392.
[50] Mancini, JA; O´Neill, GP; Bayly, C; Vickers, PJ. Mutation of serine-516 in human
prostaglandin G/H synthase-2 to methionine or aspirin acetylation of this residue
stimulates 15-R-HETE synthesis. FEBS Letters 1994, 342, 33-37.
[51] Perreti, M; Chiang, N; La, M; Fierro, IM; Marullo, S; Getting, SJ; Solito, E; Serhan,
CN. Endogenous lipid- and peptide-derived anti-inflammatory pathways generated with
glucocorticoid and aspirin treatment activate the lipoxin A4 receptor. Nature Medicine,
2002, 8, 1296-1302.
[52] Serhan, CN. Lipoxin biosynthesis and its impact in inflammatory and vascular events.
Biochimica et biphysica acta, 1994, 1212, 1-25.